Cargando…

Generation of a monoclonal antibody against the glycosylphosphatidylinositol-linked protein Rae-1 using genetically engineered tumor cells

BACKGROUND: Although genetically engineered cells have been used to generate monoclonal antibodies (mAbs) against numerous proteins, no study has used them to generate mAbs against glycosylphosphatidylinositol (GPI)-anchored proteins. The GPI-linked protein Rae-1, an NKG2D ligand member, is responsi...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Jiemiao, Vien, Long T, Xia, Xueqing, Bover, Laura, Li, Shulin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3916315/
https://www.ncbi.nlm.nih.gov/pubmed/24495546
http://dx.doi.org/10.1186/1480-9222-16-3
_version_ 1782302691683205120
author Hu, Jiemiao
Vien, Long T
Xia, Xueqing
Bover, Laura
Li, Shulin
author_facet Hu, Jiemiao
Vien, Long T
Xia, Xueqing
Bover, Laura
Li, Shulin
author_sort Hu, Jiemiao
collection PubMed
description BACKGROUND: Although genetically engineered cells have been used to generate monoclonal antibodies (mAbs) against numerous proteins, no study has used them to generate mAbs against glycosylphosphatidylinositol (GPI)-anchored proteins. The GPI-linked protein Rae-1, an NKG2D ligand member, is responsible for interacting with immune surveillance cells. However, very few high-quality mAbs against Rae-1 are available for use in multiple analyses, including Western blotting, immunohistochemistry, and flow cytometry. The lack of high-quality mAbs limits the in-depth analysis of Rae-1 fate, such as shedding and internalization, in murine models. Moreover, currently available screening approaches for identifying high-quality mAbs are excessively time-consuming and costly. RESULTS: We used Rae-1–overexpressing CT26 tumor cells to generate 60 hybridomas that secreted mAbs against Rae-1. We also developed a streamlined screening strategy for selecting the best anti–Rae-1 mAb for use in flow cytometry assay, enzyme-linked immunosorbent assay, Western blotting, and immunostaining. CONCLUSIONS: Our cell line–based immunization approach can yield mAbs against GPI-anchored proteins, and our streamlined screening strategy can be used to select the ideal hybridoma for producing such mAbs.
format Online
Article
Text
id pubmed-3916315
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-39163152014-02-07 Generation of a monoclonal antibody against the glycosylphosphatidylinositol-linked protein Rae-1 using genetically engineered tumor cells Hu, Jiemiao Vien, Long T Xia, Xueqing Bover, Laura Li, Shulin Biol Proced Online Methodology BACKGROUND: Although genetically engineered cells have been used to generate monoclonal antibodies (mAbs) against numerous proteins, no study has used them to generate mAbs against glycosylphosphatidylinositol (GPI)-anchored proteins. The GPI-linked protein Rae-1, an NKG2D ligand member, is responsible for interacting with immune surveillance cells. However, very few high-quality mAbs against Rae-1 are available for use in multiple analyses, including Western blotting, immunohistochemistry, and flow cytometry. The lack of high-quality mAbs limits the in-depth analysis of Rae-1 fate, such as shedding and internalization, in murine models. Moreover, currently available screening approaches for identifying high-quality mAbs are excessively time-consuming and costly. RESULTS: We used Rae-1–overexpressing CT26 tumor cells to generate 60 hybridomas that secreted mAbs against Rae-1. We also developed a streamlined screening strategy for selecting the best anti–Rae-1 mAb for use in flow cytometry assay, enzyme-linked immunosorbent assay, Western blotting, and immunostaining. CONCLUSIONS: Our cell line–based immunization approach can yield mAbs against GPI-anchored proteins, and our streamlined screening strategy can be used to select the ideal hybridoma for producing such mAbs. BioMed Central 2014-02-04 /pmc/articles/PMC3916315/ /pubmed/24495546 http://dx.doi.org/10.1186/1480-9222-16-3 Text en Copyright © 2014 Hu et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Methodology
Hu, Jiemiao
Vien, Long T
Xia, Xueqing
Bover, Laura
Li, Shulin
Generation of a monoclonal antibody against the glycosylphosphatidylinositol-linked protein Rae-1 using genetically engineered tumor cells
title Generation of a monoclonal antibody against the glycosylphosphatidylinositol-linked protein Rae-1 using genetically engineered tumor cells
title_full Generation of a monoclonal antibody against the glycosylphosphatidylinositol-linked protein Rae-1 using genetically engineered tumor cells
title_fullStr Generation of a monoclonal antibody against the glycosylphosphatidylinositol-linked protein Rae-1 using genetically engineered tumor cells
title_full_unstemmed Generation of a monoclonal antibody against the glycosylphosphatidylinositol-linked protein Rae-1 using genetically engineered tumor cells
title_short Generation of a monoclonal antibody against the glycosylphosphatidylinositol-linked protein Rae-1 using genetically engineered tumor cells
title_sort generation of a monoclonal antibody against the glycosylphosphatidylinositol-linked protein rae-1 using genetically engineered tumor cells
topic Methodology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3916315/
https://www.ncbi.nlm.nih.gov/pubmed/24495546
http://dx.doi.org/10.1186/1480-9222-16-3
work_keys_str_mv AT hujiemiao generationofamonoclonalantibodyagainsttheglycosylphosphatidylinositollinkedproteinrae1usinggeneticallyengineeredtumorcells
AT vienlongt generationofamonoclonalantibodyagainsttheglycosylphosphatidylinositollinkedproteinrae1usinggeneticallyengineeredtumorcells
AT xiaxueqing generationofamonoclonalantibodyagainsttheglycosylphosphatidylinositollinkedproteinrae1usinggeneticallyengineeredtumorcells
AT boverlaura generationofamonoclonalantibodyagainsttheglycosylphosphatidylinositollinkedproteinrae1usinggeneticallyengineeredtumorcells
AT lishulin generationofamonoclonalantibodyagainsttheglycosylphosphatidylinositollinkedproteinrae1usinggeneticallyengineeredtumorcells